03:42 PM EST - Amorfix Life Sciences Ltd. : announced that it has completed a series of studies with its lead anti-PrP antibody that demonstrate specific, dose-related killing of ovarian tumor cells. The Company's tumor-specific anti-PrP antibody was coupled to a toxic payload (urease) through collaboration with Helix Biopharma, and retained its specific binding to tumour cells without binding to normal ovarian cells. Amorfix Life Sciences Ltd.
shares T.AMF are trading up $0.105 at $0.33.
